<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2810200249
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Demexa
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DEXMEDETOMIDINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        498.40
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Gland Pharma Limited " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Gland Pharma Limited 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2096]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Boston Oncology Arabia
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Boston Oncology Arabia
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N05CM18
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Dexmedetomidine Hydrochloride Injection is associated with the following serious adverse reactions:<br />&bull; Hypotension, bradycardia and sinus arrest<br />&bull; Transient hypertension.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Pharmacotherapeutic group: Psycholeptics, other hypnotics and sedatives.<br />Dexmedetomidine Hydrochloride Injection contains an active substance called dexmedetomidine which belongs to a medicine group called sedatives it is used to provide sedation (a state of calm, drowsiness or sleep) for adult patients in hospital intensive care settings or awake sedation during different diagnostic or surgical procedures.</p><p>&nbsp;</p><p>a. Do not take Dexmedetomidine Hydrochloride Injection<br />-if you are allergic to dexmedetomidine or any of the other ingredients of this medicine<br />(listed in section 7a).<br />- if you have some disorders of heart rhythm (heart block grade 2 or 3).<br />- if you have very low blood pressure which does not respond to treatment.<br />- if you have recently had a stroke or other serious condition affecting blood supply to the brain.</p><p>&nbsp;</p><p>b. Take special care with Dexmedetomidine Hydrochloride Injection<br />Before you have this medicine, tell your doctor or nurse if any of the following apply as<br />Dexmedetomidine Hydrochloride Injection should be used cautiously:<br />- if you have an abnormally slow heart rate (either due to illness or high levels of physical fitness)<br />- if you have low blood pressure<br />- if you have low blood volume, for example after bleeding<br />- if you have certain heart disorders<br />- if you are elderly<br />- if you have a neurological disorder (for instance head or spinal cord injury or stroke)</p><p>- if you have severe liver problems<br />- if you have ever developed a serious fever after some medicines, especially anaesthetics</p><p>&nbsp;</p><p>c. Taking other medicines<br />Tell your doctor or nurse if you are taking, have recently taken or might take any other medicines.The following medicines may enhance the effect of Dexmedetomidine Hydrochloride Injection<br />- medicines that help you sleep or cause sedation (e.g. propofol, midazolam)<br />- strong pain medicines (e.g. opioids such as morphine, codeine)<br />- anaesthetic medicines (e.g. sevoflurane, isoflurane)</p><p>&nbsp;</p><p>If you are using medicines which lower your blood pressure and heart rate, coadministration with Dexmedetomidine Hydrochloride Injection may enhance this effect. Dexmedetomidine Hydrochloride Injection should not be used with medicines that cause temporary paralysis.</p><p>&nbsp;</p><p>d. Taking Dexmedetomidine Hydrochloride Injection with food and drink Medicines can interact with certain foods. In some cases, this may be harmful and your doctor may advise you to avoid certain foods. In the case of Dexmedetomidine&nbsp; Hydrochloride Injection there are no specific foods that you must exclude from your diet when receiving this medication.</p><p><br />e. Pregnancy and breast-feeding<br />Dexmedetomidine Hydrochloride Injection should not be used during pregnancy or breast-feeding unless clearly necessary.</p><p>Ask your doctor for advice before having this medicine</p><p>&nbsp;</p><p>f. Driving and using machines<br />Dexmedetomidine Hydrochloride Injection has major impact on the ability to drive and use machines. After you have been given Dexmedetomidine Hydrochloride Injection you must not drive, operate machinery, or work in dangerous situations until the effects are completely gone. Ask your doctor when you can start doing these activities again and when you can go back to this kind of work.</p><p><br />g. Important information about some of the ingredients of Dexmedetomidine<br />Hydrochloride Injection.</p><p>Dexmedetomidine Hydrochloride Injection contains less than 1 mmol sodium per ml, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Injection Hospital intensive care</strong><br />Dexmedetomidine Hydrochloride Injection is administered to you by a doctor or nurse in hospital intensive care.</p><p><br /><strong>Procedural sedation</strong><br />Dexmedetomidine Hydrochloride Injection is administered to you by a doctor or a nurse prior to and/or during diagnostic or surgical procedures requiring sedation, i.e.procedural/awake sedation.</p><p>Your doctor will decide on a suitable dose for you. The amount of Dexmedetomidine Hydrochloride Injection depends on your age, size, general condition of health, the level of sedation needed and how you respond to the medicine.</p><p>Your doctor may change your dose if needed and will monitor your heart and blood pressure during the treatment.</p><p>Dexmedetomidine Hydrochloride Injection is diluted and it is given to you as an infusion (drip) into your veins.</p><p>&nbsp;</p><p><strong>After sedation/wake-up</strong><br />- The doctor will keep you under medical supervision for some hours after the sedation to make sure that you feel well.<br />- You should not go home unaccompanied.<br />- Medicines to help you sleep, cause sedation or strong painkillers may not be appropriate</p><p>for some time after you have been given Dexmedetomidine Hydrochloride Injection.<br />Talk to your doctor about the use of these medicines and about the use of alcohol.</p><p>&nbsp;</p><p><strong>If you have been given more Dexmedetomidine Hydrochloride Injection than you should</strong><br />If you are given too much Dexmedetomidine hydrochloride injection, your blood pressure&nbsp; may go up or down, your heartbeat may slow down, you may breathe more slowly and you may feel more drowsy. Your doctor will know how to treat you based on your condition.<br />If you have any further questions on the use of this medicine, ask your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><br /><strong>Very common (affects more than 1 user in 10)</strong><br />- slow heart rate<br />- low or high blood pressure<br />- change in breathing pattern or stopping breathing.</p><p><br /><strong>Common (affects 1 to 10 users in 100)</strong><br />- chest pain or heart attack<br />- fast heart rate<br />- low or high blood sugar<br />- nausea, vomiting, or dry mouth<br />- restlessness<br />- high temperature<br />- symptoms after stopping the medicine</p><p><br /><strong>Uncommon side effects (affects 1 to 10 users in 1,000)</strong><br />- reduced heart function<br />- swelling of the stomach<br />- thirst<br />- a condition where there is too much acid in the body<br />- low albumin level in blood<br />- shortness of breath<br />- hallucinations<br />- the medicine is not effective enough.</p><p><br /><strong>Not known (frequency cannot be estimated from the available data)</strong><br />- increased need to pass urine</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Store below 30&deg; C. Do not use this medicine after the expiry date which is stated on the<br />label and carton after EXP.</p><p><br />This medicine does not require any special temperature storage conditions. Keep the<br />ampoules or vials in the outer carton in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- The active substance is Dexmedetomidine Hydrochloride<br />- The other ingredients are- Sodium Chloride and Water for Injection</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Dexmedetomidine Hydrochloride Injection is a clear, colourless sterile solution for Injection. The product is packed as 200 mcg in 2 mL USP Type I flint clear glass tubular vial, stoppered with 13 mm ready to sterilize Teflon coated rubber stopper sealed with 13 mm aluminium flip-off seal.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>MAH and Secondary packaging:</strong></p><p>Boston Oncology Arabia</p><p>Sudair Industrial City,</p><p>Sudair, Saudi Arabia</p><p>&nbsp;</p><p><strong>Full Manufacturing and Primary Packaging:</strong></p><p>Gland Pharma Limited</p><p>&nbsp;</p><p>To report any side effect(s):<br />&bull; Saudi Arabia:</p><p>The National Pharmacovigilance Centre (NPC)<br />- SFDA Call Centre: 19999<br />- E-mail: npc.drug@sfda.gov.sa<br />- Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>Other GCC States:</p><p>&nbsp;Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                10/2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يرتبط دواء ديكسميديتوميدين هيدروكلوريد حقن بردود الفعل الخطيرة التالية:&nbsp;<br />&bull; انخفاض ضغط الدم، بطء القلب ، واحتباس الجيوب األنفية.&nbsp;<br />&bull; ارتفاع ضغط دم عابر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>مجموعة الادوية: مضادات نفسية، منومات أخرى، ومهدئات.<br />يحتوي ديكسميديتوميدين هيدروكلوريد حقن على مادة فعالة تسمى ديكسميديتوميدين التي تنتمي إلى&nbsp;مجموعة أدوية تسمى المهدئات تستخدم لتوفير التهدئة ) وهي حالة من الهدوء، والنعاس أو النوم( للمرضى&nbsp;البالغين في أماكن العناية المركزة بالمستشفيات أو للتخدير اليقظ أثناء إجراءات التشخيص المختلفة أو&nbsp; العمليات الجراحية)</p><p>&nbsp;</p><p><strong>أ - لا&nbsp;تأخذ دواء ديكسميديتوميدين هيدروكلوريد حقن.&nbsp;</strong><br />- إذا كنت تعاني من حساسية من ديكسميديتوميدين أو أي من المكونات األخرى لهذا الدواء (المذكورة في&nbsp;<br />القسم 7-أ).&nbsp;<br />- إذا كان لديك بعض اضطرابات في ضربات نظم القلب (انسداد قلبي من الدرجة 2 أو3 )<br />- إذا كان لديك ضغط دم منخفض للغاية ال يستجيب للعالج.<br />- إذا كنت قد تعرضت مؤخرا لسكتة دماغية أو حالة خطيرة أخرى تؤثر على تدفق الدم إلى الدماغ.</p><p>&nbsp;</p><p><strong>ب - اتخذ عناية خاصة مع دواء ديكسميديتوميدين هيدروكلوريد حقن.&nbsp;</strong></p><p>قبل أن تتلقى هذا الدواء، أخبر طبيبك أو الممرضة إذا كان أي من الحالات التالية تنطبق عليك؛ مما يستدعي اتخاذ الحذر عند استخدام دواء ديكسميديتوميدين هيدروكلوريد حقن:&nbsp;</p><p>- إذا كان لديك معدل ضربات قلب بطيء غير طبيعي (إما بسبب مرض أو مستويات عالية من اللياقة البدنية).&nbsp;</p><p>- إذا كان لديك انخفاض في ضغط الدم.&nbsp;</p><p>- إذا كان لديك حجم دم منخفض، مثلاً: بعد النزيف.&nbsp;</p><p>- إذا كان لديك اضطرابات معينة في القلب.&nbsp;</p><p>- إذا كنت من كبار السن.&nbsp;</p><p>- إذا كان لديك اضطراب عصبي (مثلاً: إصابة في الرأس أو الحبل الشوكي أو السكتة الدماغية).&nbsp;</p><p>- إذا كان لديك مشاكل شديدة في الكبد.&nbsp;</p><p>- إذا حصل عندك حمى خطيرة بعد تناول بعض الأدوية، وبخاصةً أدوية التخدير.&nbsp;</p><p>&nbsp;</p><p><strong>ج - تناول أدوية أخرى.&nbsp;</strong></p><p>أخبر طبيبك أو ممرضتك إذا كنت قد تناولت، أو أخذت مؤخراً أو ربما تأخذ أية أدوية أخرى.&nbsp;</p><p>الأدوية التالية قد تعزز من تأثير ديكسميديتوميدين هيدروكلوريد حقن:&nbsp;</p><p>- الأدوية التي تساعدك على النوم أو تسبب التهدئة (مثلاً: بروبوفول، ميدازولام).&nbsp;</p><p>- أدوية الآلام القوية (مثلاً: المواد الأفيونية مثلاً: المورفين، الكودئين).&nbsp;</p><p>- أدوية التخدير (مثلاً: سيفوفلوران، آيزوفلوران).&nbsp;</p><p>&nbsp;</p><p>إذا كنت تستخدم أدوية خافضة لضغط دمك ولمعدل ضربات القلب، فإن مشاركتها مع ديكسميديتوميدين هيدروكلوريد حقن قد يعزز هذا التأثير. لا ينبغي استخدام ديكسميديتوميدين هيدروكلوريد حقن مع الأدوية التي تسبب الشلل المؤقت.&nbsp;</p><p>&nbsp;</p><p><strong>د - تناول ديكسميديتوميدين هيدروكلوريد حقن مع الطعام والشراب.&nbsp;</strong></p><p>يمكن أن تتفاعل الأدوية مع بعض الأطعمة. في بعض الحالات، قد يكون هذا ضاراً وقد ينصحك طبيبك بتجنب بعض الأطعمة. في حالة تناول دواء ديكسميديتوميدين هيدروكلوريد حقن لا يوجد أطعمة محددة يجب عليك استبعادها من نظامك الغذائي.&nbsp;</p><p>&nbsp;</p><p><strong>هـ - الحمل والرضاعة الطبيعية.&nbsp;</strong></p><p>لا ينبغي استخدام ديكسميديتوميدين هيدروكلوريد حقن أثناء الحمل أو الرضاعة الطبيعية ما لم يكن ذلك ضرورياً بشكل واضح.&nbsp;</p><p>اطلب مشورة طبيبك قبل تناول هذا الدواء.&nbsp;</p><p>&nbsp;</p><p><strong>و - القيادة واستخدام الآلات.&nbsp;</strong></p><p>إن دواء ديكسميديتوميدين هيدروكلوريد حقن له تأثير كبير على قدرة القيادة واستخدام الآلات. يجب عليك بعد إعطائك دواء ديكسميديتوميدين هيدروكلوريد حقن عدم القيادة، أو تشغيل الآلات، أو العمل في الأحوال الخطرة حتى تتلاشى آثار الدواء تماماً. اسأل طبيبك متى يمكنك البدء بالقيام بهذه الأنشطة من جديد ومتى يمكنك العودة إلى هذا النوع من العمل.&nbsp;</p><p>&nbsp;</p><p><strong>ز - معلومات مهمة حول بعض مكونات دواء ديكسميديتوميدين هيدروكلوريد حقن.&nbsp;</strong></p><p>يحتوي دواء ديكسميديتوميدين هيدروكلوريد حقن على أقل من 1 مليمول من الصوديوم في الميليليتر الواحد، وهذا يعني بشكل أساسي &quot;خالي من الصوديوم&quot;.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>العناية المركزة بالمستشفى.&nbsp;</strong></p><p>يُوصف دواء ديكسميديتوميدين هيدروكلوريد حقن لك من قبل طبيب أو ممرضة في العناية المركزة بالمستشفى.&nbsp;</p><p>&nbsp;</p><p><strong>التخدير الإجرائي.&nbsp;</strong></p><p>يُعطى دواء ديكسميديتوميدين هيدروكلوريد حقن لك من قبل طبيب أو ممرضة قبل و/أو خلال إجراءات التشخيص أو العمليات الجراحية التي تتطلب التخدير، أي التخدير الإجرائي / اليقظ.&nbsp;</p><p>&nbsp;</p><p>سيقرر طبيبك الجرعة المناسبة لك. تعتمد كمية دواء ديكسميديتوميدين هيدروكلوريد حقن على عمرك، وحجمك، وحالتك الصحية العامة، وعلى مستوى التخدير اللازم وعلى كيفية استجابتك للعلاج.&nbsp;</p><p>قد يغير طبيبك جرعتك إذا لزم الأمر وسيراقب قلبك وضغط دمك أثناء المعالجة.&nbsp;</p><p>يتم تخفيف دواء ديكسميديتوميدين هيدروكلوريد حقن ويعطى لك بالتشريب (التنقيط) في أوردتك.&nbsp;</p><p>&nbsp;</p><p><strong>بعد التخدير أو الاستيقاظ.&nbsp;</strong></p><p>- سيبقيك الطبيب تحت الإشراف الطبي لبضعة ساعات بعد التهدئة للتأكد من تحسُّن حالتك.&nbsp;</p><p>- يجب عليك ألا تذهب إلى البيت بدون مرافقة.&nbsp;</p><p>- إن الأدوية التي تساعدك على النوم، تسبب التخدير أو أن المسكنات القوية قد لا تكون مناسبة لبعض الوقت بعد إعطائك دواء ديكسميديتوميدين هيدروكلوريد حقن. تحدث مع طبيبك حول استخدام هذه الأدوية وعن استخدام الكحول.&nbsp;</p><p>&nbsp;</p><p><strong>إذا أُعطي لك المزيد من دواء ديكسميديتوميدين هيدروكلوريد حقن أكثر مما ينبغي.&nbsp;</strong></p><p>إذا تم إعطاؤك الكثير من دواء ديكسميديتوميدين هيدروكلوريد حقن، فقد يرتفع أو ينخفض ضغط دمك​​، وقد يبطئ قلبك، وقد تتنفس ببطء أكثر وقد تشعر بالنعاس أكثر. سيعرف طبيبك كيف يعالجك وفقاً لحالتك.&nbsp;</p><p>إذا كان لديك أية أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء تأثيرات جانبية، وإن كانت لا تحدث لكل شخص.</p><p dir="RTL">&nbsp;</p><p dir="RTL">شائعة جداً&nbsp;<em>(تؤثر في أكثر من 1 مستخدم من 10)</em></p><p dir="RTL">- معدل ضربات قلب بطيء.</p><p dir="RTL">- انخفاض أو ارتفاع ضغط الدم.</p><p dir="RTL">- تغير في نمط التنفس أو وقف التنفس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">شائعة<em>&nbsp;(تؤثر في&nbsp;&nbsp;1مستخدم&nbsp;&nbsp;إلى 10 من 100)</em></p><p dir="RTL">- ألم في الصدر أو نوبة قلبية.</p><p dir="RTL">- سرعة ضربات القلب.</p><p dir="RTL">- انخفاض أو ارتفاع السكر في الدم.</p><p dir="RTL">- غثيان, إقياء, أو جفاف الفم.</p><p dir="RTL">- أرق.</p><p dir="RTL">- حرارة عالية.</p><p dir="RTL">- أعراض بعد وقف تناول الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تأثيرات جانبية غير شائعة<em>&nbsp;&nbsp;(تؤثر في&nbsp;&nbsp;1مستخدم&nbsp;&nbsp;إلى 10 من 1000)</em></p><p dir="RTL">- انخفاض وظيفة القلب.</p><p dir="RTL">- انتفاخ المعدة.</p><p dir="RTL">- العطش.</p><p dir="RTL">- حالة يكون فيها الحمض كثيراً جداً في الجسم.</p><p dir="RTL">- انخفاض مستوى الزلال في الدم.</p><p dir="RTL">- ضيق في التنفس.</p><p dir="RTL">- الهلوسة.</p><p dir="RTL">- الدواء غير فعال بما فيه الكفاية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">غير معروفة<em>&nbsp;(لا يمكن تقدير تكرارها من البيانات المتاحة)</em></p><p dir="RTL">- زيادة الحاجة للتبول.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن رؤية ومتناول الأطفال.</p><p dir="RTL">احفظه في البراد بدرجة حرارة 30&deg; مئوية. لا تستعمل هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على اللصاقة والعلبة بعد&nbsp;EXP.</p><p dir="RTL">هذا الدواء لا يتطلب أية شروط خاصة بدرجة الحرارة للتخزين. احفظ الحُبابات أو القوارير في العلبة الخارجية لحمايتها من الضوء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">- المادة الفعالة هي: ديكسميديتوميدين هيدروكلوريد.</p><p dir="RTL">- المكونات الأخرى هي: كلوريد الصوديوم و ماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">إن&nbsp;<strong>ديكسميديتوميدين هيدروكلوريد حقن</strong>&nbsp;هو عبارة عن محلول رائق, عديم اللون معقم للحقن. تمت تعبئة هذا المنتج بكمية 200 مكغ في 2 مل بقارورة زجاجية أنبوبية صافية نوع أول وفق دستور الأدوية الأمريكي, مغلقة بسدادة مطاطية قطر 13 مم جاهزة للتعقيم مطلية بمادة التيفلون ومختومة بغطاء ألمنيوم قطر 13 مم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><em>أ&zwnj;-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em><em>مالك حقوق التسويق والتغليف الثانوي: </em></p><p dir="RTL"><em>شركة بوستن اونكولجي العربية </em></p><p dir="RTL">&nbsp;</p><p dir="RTL">منطقة سدير الصناعية، سدير، المملكة العربية السعودية</p><p dir="RTL"><em>ب&zwnj;-&nbsp; </em><em>التصنيع الكامل والتغليف الأولي: </em></p><p dir="RTL">قلاند فارما المحدودة</p><p dir="RTL">&nbsp;</p><p><strong>للإبلاغ عن أية تأثيرات جانبية:&nbsp;</strong></p><p><strong>المملكة العربية السعودية:&nbsp;</strong></p><p>&bull;مركز التيقظ الدوائي الوطني The National Pharmacovigilance Centre (NPC)&nbsp;</p><p>-رقم هيئة الغذاء والدواء السعودية: 19999&nbsp;</p><p>-البريد الإلكتروني: npc.drug@sfda.gov.sa&nbsp;</p><p>-موقع الشبكة: https://ade.sfda.gov.sa/&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>&bull; دول مجلس التعاون الخليجي الأخرى:&nbsp;</strong></p><p>&nbsp;</p><p>- يرجى الاتصال بالهيئة المختصة ذات الصلة.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            10/2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dexmedetomidine Hydrochloride Injection 100 mcg/ml
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains 100 micrograms of dexmedetomidine. For a full list of excipients, see section 6.1

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dexmedetomidine Hydrochloride Injection is a sterile solution for Injection The concentrate is a clear, colourless solution
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dexmedetomidine Hydrochloride Injection is a relatively selective alpha2-adrenergic agonist indicated for:</p><ul><li><strong>Intensive Care Unit Sedation</strong></li></ul><p>Dexmedetomidine Hydrochloride Injection is indicated for sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting. Dexmedetomidine Hydrochloride Injection should be administered by continuous infusion not to exceed 24 hours.</p><p>Dexmedetomidine Hydrochloride Injection has been continually infused in mechanically ventilated patients prior to extubation, during extubation, and post-extubation. It is not necessary to discontinue Dexmedetomidine Hydrochloride Injection prior to extubation.</p><ul><li><strong>Procedural Sedation</strong></li></ul><p>Dexmedetomidine Hydrochloride Injection is indicated for sedation of non-intubated patients prior to and/or during surgical and other procedures.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dexmedetomidine Hydrochloride Injection should be individualized and titrated to desired clinical response.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dexmedetomidine Hydrochloride Injection is not indicated for infusions lasting longer than 24 hours.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dexmedetomidine Hydrochloride Injection should be administered using a controlled infusion device.</p><p>Table 1: Dosage Information</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>INDICATION</strong></p></td><td style="vertical-align:top"><p><strong>DOSAGE AND ADMINISTRATION</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Initiation of Intensive Care Unit Sedation</strong></p></td><td style="vertical-align:top"><p><strong>For adult patients</strong>: a loading infusion of one mcg/kg over 10 <strong>minutes.</strong></p><p><strong>For adult patients being converted from alternate sedative therapy: </strong>a loading dose may not be required.</p><p><strong>For patients over 65 years of age: </strong>a dose reduction should be considered.</p><p><strong>For adult patients with impaired hepatic-function:</strong></p><p>a dose reduction should be considered. (see section 5)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Maintenance of Intensive Care Unit Sedation</strong></p></td><td style="vertical-align:top"><p><strong>For adult patients: </strong>a maintenance infusion of 0.2 to 0.7 mcg/kg/<strong>hour</strong>.</p><p>The rate of the maintenance infusion should be adjusted to achieve the desired level of sedation. <strong>For patients over 65 years of age: </strong>a dose reduction should be considered</p><p><strong>For adult patients with impaired hepatic function: </strong>a dose reduction should be considered</p></td></tr><tr><td style="vertical-align:top"><p><strong>Initiation of Procedural Sedation</strong></p></td><td style="vertical-align:top"><p><strong>For adult patients: </strong>a loading infusion of one mcg/kg over 10 <strong>minutes.</strong></p><p>For less invasive procedures such as ophthalmic surgery, a loading infusion of 0.5 mcg/kg given over 10 <strong>minutes </strong>may be suitable.</p><p><strong>For awake fiberoptic intubation in adult patients: </strong>a loading infusion of one mcg/kg over 10 <strong>minutes.</strong></p><p><strong>For patients over 65 years of age: </strong>a loading infusion of 0.5 mcg/kg over 10 <strong>minutes</strong></p><p><strong>For adult patients with impaired hepatic function: </strong>a dose reduction should be considered</p></td></tr><tr><td style="vertical-align:top"><p><strong>Maintenance of Procedural Sedation</strong></p></td><td style="vertical-align:top"><p><strong>For adult patients: </strong>the maintenance infusion is generally initiated at 0.6 mcg/kg/<strong>hour </strong>and titrated to achieve desired clinical effect with doses ranging from 0.2 to 1 mcg/kg/<strong>hour</strong>. The rate of the maintenance infusion should be adjusted to achieve the targeted level of sedation.</p><p><strong>For awake fiberoptic intubation in adult patients: </strong>a maintenance infusion of 0.7 mcg/kg/<strong>hour </strong>is recommended until the endotracheal tube is secured.</p><p><strong>For patients over 65 years of age: </strong>a dose reduction should be considered</p><p><strong>For adult patients with impaired hepatic function: </strong>a dose reduction should be considered</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Dosage Adjustment</strong></p><p>Due to possible pharmacodynamic interactions, a reduction in dosage of Dexmedetomidine Hydrochloride Injection or other concomitant anesthetics, sedatives, hypnotics or opioids may be required when co-administered.</p><p>Dosage reductions may need to be considered for <strong>adult </strong>patients with hepatic impairment, and geriatric patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
•	Advanced heart block (grade 2 or 3) unless paced.
•	Uncontrolled hypotension
•	Acute cerebrovascular conditions.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Monitoring</u></strong></p><p>Dexmedetomidine Hydrochloride Injection is intended for use in an intensive care setting, operating room and during diagnostic procedures. The use in other environments is not recommended. All patients should have continuous cardiac monitoring during Dexmedetomidine Hydrochloride Injection. Respiration should be monitored in non-intubated patients due to the risk of respiratory depression and in some case apnoea (see section 4.8).</p><p>The time to recovery after the use of dexmedetomidine was reported to be approximately one hour. When used in an outpatient setting close monitoring should continue for at least one hour (or longer based on the patient condition), with medical supervision continued for at least one further hour to ensure the safety of the patient.</p><p>&nbsp;</p><p><strong><u>General precautions</u></strong></p><p>Dexmedetomidine Hydrochloride Injection should not be given as a bolus dose and in the ICU a loading dose is not recommended. Users should therefore be ready to use an alternative sedative for acute control of agitation or during procedures, especially during the first few</p><p>hours of treatment. During procedural sedation a small bolus of another sedative may be used if a rapid increase in sedation level is required.</p><p>Some patients receiving Dexmedetomidine Hydrochloride Injection have been observed to be arousable and alert when stimulated. This alone should not be considered as evidence of lack of efficacy in the absence of other clinical signs and symptoms.</p><p>Dexmedetomidine normally does not cause deep sedation and patients may be easily roused. Dexmedetomidine is therefore not suitable in patients who will not tolerate this profile of effects, for example those requiring continuous deep sedation.</p><p>Dexmedetomidine Hydrochloride Injection should not be used as a general anaesthetic induction agent for intubation or to provide sedation during muscle relaxant use.</p><p>Dexmedetomidine lacks the anticonvulsant action of some other sedatives and so will not suppress underlying seizure activity.</p><p>Care should be taken if combining dexmedetomidine with other substances with sedative or cardiovascular actions as additive effects may occur.</p><p>Dexmedetomidine Hydrochloride Injection is not recommended for patient controlled sedation. Adequate data is not available.</p><p>When Dexmedetomidine Hydrochloride Injection is used in an outpatient setting patients should normally be discharged into the care of a suitable third party. Patients should be advised to refrain from driving or other hazardous tasks and where possible to avoid the use of other agents that may sedate (e.g, benzodiazepines, opioids, alcohol) for a suitable period of time based on observed effects of dexmedetomidine, the procedure, concomitant medications, the age and the condition of the patient.</p><p>Caution should be exercised when administering dexmedetomidine to elderly patients. Elderly patients over 65 years of age may be more prone to hypotension with the administration of dexmedetomidine, including a loading dose, for procedures. A dose reduction should be considered.</p><p>&nbsp;</p><p><strong><u>Cardio-vascular effects and precautions</u></strong></p><p>Dexmedetomidine reduces heart rate and blood pressure through central sympatholysis but at higher concentrations causes peripheral vasoconstriction leading to hypertension (see section 5.1). Dexmedetomidine is therefore not suitable in patients with severe cardiovascular instability.</p><p>Caution should be exercised when administering dexmedetomidine to patients with pre- existing bradycardia. Data on the effects of Dexmedetomidine Hydrochloride Injection in patients with heart rate &lt;60 are very limited and particular care should be taken with such patients. Bradycardia does not normally require treatment, but has commonly responded to anti-cholinergic medicine or dose reduction where needed. Patients with high physical fitness and slow resting heart rate may be particularly sensitive to bradycardic effects of alpha-2 receptor agonists and cases of transient sinus arrest have been reported.</p><p>The hypotensive effects of dexmedetomidine may be of greater significance in those patients with pre-existing hypotension (especially if not responsive to vasopressors), hypovolaemia, chronic hypotension or reduced functional reserve such as patients with severe ventricular dysfunction and the elderly and special care is warranted in these cases (see section 4.3). Hypotension does not normally require specific treatment but, where needed, users should be ready to intervene with dose reduction, fluids and/or vasoconstrictors.</p><p>Patients with impaired peripheral autonomic activity (e.g. due to spinal cord injury) may have more pronounced haemodynamic changes after starting dexmedetomidine and so should be treated with care.</p><p>Transient hypertension has been observed primarily during the loading dose in association with the peripheral vasoconstrictive effects of dexmedetomidine and a loading dose is not recommended in ICU sedation. Treatment of hypertension has generally not been necessary but decreasing the continuous infusion rate may be advisable.</p><p>Local vasoconstriction at higher concentration may be of greater significance in patients with ischaemic heart disease or severe cerebrovascular disease who should be monitored closely. Dose reduction or discontinuation should be considered in a patient developing signs of myocardial or cerebral ischaemia.</p><p>Caution is advised when administering dexmedetomidine together with spinal or epidural anaesthesia due to possible increased risk of hypotension or bradycardia.</p><p>&nbsp;</p><p><strong><u>Patients with hepatic impairment</u></strong></p><p>Care should be taken in severe hepatic impairment as excessive dosing may increase the risk of adverse reactions, over-sedation or prolonged effect as a result of reduced dexmedetomidine clearance.</p><p>&nbsp;</p><p><strong><u>Patients with neurological disorders</u></strong></p><p>Experience of dexmedetomidine in severe neurological disorders such as head injury and after neurosurgery is limited and it should be used with caution here, especially if deep sedation is required. Dexmedetomidine may reduce cerebral blood flow and intracranial pressure and this should be considered when selecting therapy.</p><p>&nbsp;</p><p><strong><u>Other</u></strong></p><p>Alpha-2 agonists have rarely been associated with withdrawal reactions when stopped abruptly after prolonged use. This possibility should be considered if the patient develops agitation and hypertension shortly after stopping dexmedetomidine.</p><p>Dexmedetomidine may induce hyperthermia and in isolated cases temperatures &ge; 42&deg;C have been reported. Hyperthermia can be resistant to traditional cooling methods. Dexmedetomidine Hydrochloride Injection treatment should be discontinued in the event of unexplained high fever. It is not recommended to use Dexmedetomidine Hydrochloride Injection in malignant hyperthermia-sensitive patients.</p><p>Dexmedetomidine Hydrochloride Injection contains less than 1 mmol sodium per ml.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interaction studies have only been performed in adults.</p><p>Co-administration of dexmedetomidine with anaesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects, including sedative, anaesthetic and cardiorespiratory effects. Specific studies have confirmed enhanced effects with isoflurane, propofol, alfentanil, and midazolam.</p><p>No pharmacokinetic interactions between dexmedetomidine and isoflurane, propofol, alfentanil and midazolam have been demonstrated. However, due to possible pharmacodynamic interactions, when co-administered with dexmedetomidine, a reduction in dosage of dexmedetomidine or the concomitant anaesthetic, sedative, hypnotic or opioid may be required.</p><p>Inhibition of CYP enzymes including CYP2B6 by dexmedetomidine has been studied in human liver microsome incubations. In vitro study suggests that interaction potential in vivo exists between dexmedetomidine and substrates with dominant CYP2B6 metabolism.</p><p>Induction of dexmedetomidine in vitro was observed on CYP1A2, CYP2B6, CYP2C8, CYP2C9 and CYP3A4, and induction in vivo cannot be excluded. The clinical significance is unknown.</p><p>The possibility of enhanced hypotensive and bradycardic effects should be considered in patients receiving other medicinal products causing these effects, for example beta blockers, although additional effects in an interaction study with esmolol were modest.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;<u><strong>Pregnancy</strong></u></p><p>There are no or limited amount of data from the use of dexmedetomidine in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). Dexmedetomidine Hydrochloride Injection should not be used during pregnancy unless the clinical condition of the woman requires treatment with dexmedetomidine.</p><p><u><strong>Breastfeeding</strong></u></p><p>Dexmedetomidine is excreted in human milk, however levels will be below the limit of detection by 24 hours following treatment discontinuation. A risk to infants cannot be excluded. A decision must be made whether to discontinue breastfeeding or to discontinue dexmedetomidine therapy taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.</p><p><u><strong>Fertility</strong></u></p><p>In the rat fertility study, dexmedetomidine had no effect on male or female fertility. No human data on fertility are available.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients should be advised to refrain from driving or other hazardous tasks for a suitable period of time after receiving Dexmedetomidine Hydrochloride Injection for procedural sedation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>a.&nbsp; <em>Summary of the safety profile</em></p><p><u>Intensive Care Unit Sedation</u></p><p>The most frequently reported adverse reactions with dexmedetomidine in ICU setting are hypotension, hypertension and bradycardia, occurring in approximately 25%, 15% and 13% of patients respectively.</p><p>Hypotension and bradycardia were also the most frequent dexmedetomidine-related serious adverse reactions occurring in 1.7% and 0.9% of randomised Intensive Care Unit (ICU) patients respectively.</p><p><u>Procedural sedation</u></p><p>The most frequently reported adverse reactions with dexmedetomidine in procedural sedation are listed below (the protocols of phase III studies contained pre-defined thresholds for reporting changes in blood pressure, respiratory rate and heart rate as AEs).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypotension (55 % in dexmedetomidine-group vs. 30 % in placebo-group receiving rescue midazolam and fentanyl)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Respiratory depression (38 % in dexmedetomidine-group vs. 35 % in placebo-group receiving rescue midazolam and fentanyl)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bradycardia (14 % in dexmedetomidine-group vs. 4 % in placebo-group receiving rescue midazolam and fentanyl)</p><p>&nbsp;</p><p>b.&nbsp; <em>Tabulated list of adverse reactions</em></p><p>The adverse reactions listed in Table 2 have been accumulated from pooled data of clinical trials in intensive care.</p><p>Adverse reactions are ranked under headings of frequency, the most frequent first, using the following convention: Very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000).</p><p>Table 2. Adverse reactions</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong><em>Metabolism and nutrition disorders</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Hyperglycaemia, hypoglycaemia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Metabolic acidosis, hypoalbuminaemia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong><em>Psychiatric disorders</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Agitation</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Hallucination</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong><em>Cardiac disorders</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Bradycardia<sup>1,2</sup></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Myocardial ischaemia or infarction, tachycardia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Atrioventricular block first degree, cardiac output decreased</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong><em>Vascular disorders:</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Hypotension<sup>1,2,</sup> hypertension<sup>1,2</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong><em>Respiratory, thoracic and mediastinal disorders</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Respiratory depression<sup>2,3</sup></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Dyspnoea, apnoea</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong><em>Gastrointestinal</em></strong><strong><em> </em></strong><strong><em>disorders</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Nausea<sup>2</sup>, vomiting, dry mouth<sup>2</sup></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Abdominal distension</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong><em>Renal and urinary disorders</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Polyuria</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong><em>General disorders and administration site conditions</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Withdrawal syndrome, hyperthermia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Drug ineffective, thirst</p></td></tr></tbody></table><p><sup>1</sup> See section on Description of selected adverse reactions</p><p><sup>2</sup> Adverse reaction observed also in procedural sedation studies</p><p><sup>3</sup> Incidence &#39;common&#39; in ICU sedation studies</p><p>&nbsp;</p><p>c.&nbsp; <em>Description of selected adverse reactions</em></p><p>Clinically significant hypotension or bradycardia should be treated as described in section 4.4. In relatively healthy non-ICU subjects treated with dexmedetomidine, bradycardia has occasionally led to sinus arrest or pause. The symptoms responded to leg raising and anticholinergics such as atropine or glycopyrrolate. In isolated cases bradycardia has progressed to periods of asystole in patients with pre-existing bradycardia.</p><p>Hypertension has been associated with the use of a loading dose and this reaction can be reduced by avoiding such a loading dose or reducing the infusion rate or size of the loading dose.</p><p>&nbsp;</p><p>d.&nbsp; <em>Paediatric population</em></p><p>Children &gt;1 month post-natal, predominantly post-operative, have been evaluated for treatment up to 24 hours in the ICU and demonstrated a similar safety profile as in adults. Data in new-born infants (28 &ndash; 44 weeks gestation) is very limited and restricted to maintenance doses &le; 0.2 mcg/kg/h. A single case of hypothermic bradycardia in a neonate has been reported in the literature.</p><p>&nbsp;</p><p>e.&nbsp; <em>Other special populations</em></p><p><u>Geriatric Use</u></p><p><em><u>Intensive Care Unit Sedation</u></em></p><p>A total of 729 patients in the clinical studies were 65 years of age and over. A total of 200 patients were 75 years of age and over. In patients greater than 65 years of age, a higher incidence of bradycardia and hypotension was observed following administration of Dexmedetomidine Hydrochloride Injection (see section 4.4). Therefore, a dose reduction may be considered in patients over 65 years of age. (see section 4.1 and section 5)</p><p>&nbsp;</p><p><u>Hepatic Impairment</u></p><p>Since Dexmedetomidine Hydrochloride Injection clearance decreases with increasing severity of hepatic impairment, dose reduction should be considered in patients with impaired hepatic function. (see section 4.1 and section 5).</p><p><u>To reports any side effect(s):</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Saudi Arabia:</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Centre: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p><p><br /><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1026" type="#_x0000_t75" style='width:449.6pt;height:138.05pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Other GCC States:</em></p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:shape
 id="Textbox_x0020_2" o:spid="_x0000_s1026" type="#_x0000_t202" style='width:449.6pt;
 height:14.2pt;visibility:visible;mso-wrap-style:square;mso-left-percent:-10001;
 mso-top-percent:-10001;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:char;mso-position-vertical:absolute;
 mso-position-vertical-relative:line;mso-left-percent:-10001;mso-top-percent:-10001;
 v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" strokeweight=".20458mm">
 <v:path arrowok="t"/>
 <v:textbox inset="0,0,0,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='margin-left:8.1pt;line-height:13.5pt;mso-line-height-rule:
    exactly'><span style='font-size:12.0pt;mso-bidi-font-size:11.0pt'>-<span
    style='letter-spacing:1.3pt'><span style='mso-spacerun:yes'>  </span></span></span><span
    style='font-size:11.5pt;mso-bidi-font-size:11.0pt'>Please<span
    style='letter-spacing:-.45pt'> </span>contact<span style='letter-spacing:
    -.45pt'> </span>the<span style='letter-spacing:-.3pt'> </span>relevant<span
    style='letter-spacing:-.55pt'> </span>competent<span style='letter-spacing:
    -.35pt'> </span><span style='letter-spacing:-.1pt'>authority.</span><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]-->-&nbsp; Please contact the relevant competent authority.<!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1025" type="#_x0000_t75" style='width:449.6pt;height:14.2pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Symptoms</u></strong></p><p>Several cases of dexmedetomidine overdose have been reported both in the clinical trial and the post-marketing data. The reported highest infusion rates of dexmedetomidine in these cases have reached up to 60 &mu;g/kg/h for 36 minutes and 30 &mu;g/kg/h for 15 minutes in a 20-month- old child and in an adult, respectively. The most common adverse reactions reported in conjunction with overdose include bradycardia, hypotension, hypertension, oversedation, respiratory depression and cardiac arrest.</p><p>&nbsp;</p><p><strong><u>Management</u></strong></p><p>In cases of overdose with clinical symptoms, dexmedetomidine infusion should be reduced or stopped. Expected effects are primarily cardiovascular and should be treated as clinically indicated (see section 4.4). At high concentration hypertension may be more prominent than hypotension. In clinical studies, cases of sinus arrest reversed spontaneously or responded to treatment with atropine and glycopyrrolate. Resuscitation was required in isolated cases of severe overdose resulting in cardiac arrest.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Psycholeptics, other hypnotics and sedatives, ATC code:<em>N05CM18.</em></p><p>Dexmedetomidine is a selective alpha-2 receptor agonist with a broad range of pharmacological properties. It has a sympatholytic effect through decrease of the release of noradrenaline in sympathetic nerve endings. The sedative effects are mediated through decreased firing of locus coeruleus, the predominant noradrenergic nucleus, situated in the brainstem. Dexmedetomidine has analgesic and anaesthetic/analgesic-sparing effects. The cardiovascular effects depend on the dose; with lower infusion rates the central effects dominate leading to decrease in heart rate and blood pressure. With higher doses, peripheral vasoconstricting effects prevail leading to an increase in systemic vascular resistance and blood pressure, while the bradycardic effect is further emphasised. Dexmedetomidine is relatively free from respiratory depressive effects when given as monotherapy to healthy subjects.</p><p>&nbsp;</p><p><strong><u>Intensive Care Unit Sedation</u></strong></p><p>In placebo controlled trials in a post-operative ICU population previously intubated and sedated with midazolam or propofol, Dexmedetomidine Hydrochloride Injection significantly reduced the requirement for both rescue sedative (midazolam or propofol) and opioids during sedation for up to 24 hours. Most dexmedetomidine patients required no additional sedative treatment. Patients could be successfully extubated without stopping the Dexmedetomidine Hydrochloride Injection infusion. Studies from outside the ICU have confirmed that Dexmedetomidine Hydrochloride Injection can be administered safely to patients without endotracheal intubation provided adequate monitoring is in place.</p><p>Dexmedetomidine was similar to midazolam (Ratio 1.07; 95% CI 0.971, 1.176) and propofol (Ratio 1.00; 95% CI 0.922, 1.075) on the time in target sedation range in a predominently medical population requiring prolonged light to moderate sedation (RASS 0 to -3) in the ICU for up to 14 days, reduced the duration of mechanical ventilation compared to midazolam and reduced the time to extubation compared to midazolam and propofol. Compared to both propofol and midazolam, patients were more easily roused, more cooperative and better able to communicate whether or not they had pain. Dexmedetomidine treated patients had more frequent hypotension and bradycardia but less tachycardia than those receiving midazolam and more frequent tachycardia but similar hypotension to propofol-treated patients. Delirium measured by the CAM-ICU scale was reduced in a study compared to midazolam and delirium- related adverse events were lower on dexmedetomidine compared to propofol. Those patients who withdrew due to insufficient sedation were switched to either propofol or midazolam.</p><p>&nbsp;</p><p>The risk of insufficient sedation was increased in patients who were difficult to sedate with standard care immediately prior to switching.</p><p>Evidence of paediatric efficacy was seen in a dose-controlled ICU study in a largely post- operative population aged 1 month to &le; 17 years. Approximately 50% of patients treated with dexmedetomidine did not require rescue addition of midazolam during a median treatment period of 20.3 hours, not exceeding 24 hours. Data on treatment for &gt; 24 hours is not available. Data in new-born infants (28 &ndash; 44 weeks gestation) is very limited and restricted to low doses (&le; 0.2 mcg/kg/h) (see sections 5.2 and 4.4). New-born infants may be particularly sensitive to the bradycardic effects of Dexmedetomidine Hydrochloride Injection in the presence of hypothermia and in conditions of heart rate-dependent cardiac output.</p><p>In double blind comparator controlled ICU studies the incidence of cortisol suppression in patients treated with dexmedetomidine (n=778) was 0.5% compared with 0% in patients treated with either midazolam (n=338) or propofol (n=275). The event was reported as mild in 1 and moderate in 3 cases.</p><p>&nbsp;</p><p><strong><u>Procedural sedation</u></strong></p><p>The safety and efficacy of dexmedetomidine for sedation of non-intubated patients prior to and/or during surgical and diagnostic procedures was evaluated in two randomised, double- blind, placebo-controlled multicentre clinical trials.</p><p>&middot;&nbsp;&nbsp; Study 1 randomised patients undergoing elective surgeries/procedures under monitored anaesthesia care and local/regional anaesthesia to receive a loading infusion of dexmedetomidine either 1 &mu;g/kg (n=129) or 0.5 &mu;g/kg (n=134), or placebo (normal saline; n=63) given over 10 minutes and followed by a maintenance infusion started at 0.6 &mu;g/kg/h. The maintenance infusion of study drug could be titrated from 0.2 &mu;g/kg/h to 1 &mu;g/kg/h. The proportion of patients that achieved the targeted sedation level (Observer&#39;s Assessment of Alertness/Sedation Scale &le;4) without need for rescue midazolam was 54% of the patients receiving dexmedetomidine 1 &mu;g/kg and 40% of the patients receiving dexmedetomidine 0.5 &mu;g/kg compared to 3% of patients receiving the placebo. The risk difference in proportion of subjects randomised to dexmedetomidine 1 &mu;g/kg group and dexmedetomidine 0.5 &mu;g/kg group not requiring rescue midazolam was 48% (95% CI: 37 % - 57%) and 40% (95% CI: 28% - 48%), respectively compared placebo. The median (range) midazolam rescue dose was 1.5 (0.5-7.0)&nbsp; mg&nbsp; in&nbsp; the&nbsp; dexmedetomidine1.0&nbsp; &mu;g/kg&nbsp; group,&nbsp; 2.0&nbsp; (0.5-8.0)&nbsp; mg&nbsp; in&nbsp; the dexmedetomidine 0.5 &mu;g/kg group, and 4.0 (0.5-14.0) mg in the placebo group. The difference in means in dose of rescue midazolam in dexmedetomidine 1 &mu;g/kg and dexmedetomidine 0.5 &mu;g/kg group compared to placebo was -3.1 mg (95% CI: -3.8 - -2.5) and -2.7 mg (95% CI: - 3.3 - -2.1), respectively favouring dexmedetomidine. The median time to first rescue dose was 114 minutes in the dexmedetomidine 1.0 &mu;g/kg group, 40 minutes in the dexmedetomidine 0.5 &mu;g/kg group, and 20 minutes in the placebo group.</p><p>&middot;&nbsp;&nbsp; Study 2 randomised patients undergoing awake fibreoptic intubation under topical anaesthesia to receive a loading infusion of dexmedetomidine 1 &mu;g/kg (n=55) or placebo (normal saline) (n=50) given over 10 minutes and followed by a fixed maintenance infusion of 0.7 &mu;g/kg/h. To maintain a Ramsay Sedation Scale &ge;2 53% of the patients receiving dexmedetomidine did not require midazoloam rescue vs. 14% of patients receiving placebo. The risk difference in proportion of subjects randomised to dexmedetomidine not requiring rescue midazolam was 43% (95% CI: 23 % - 57%) compared placebo. The mean midazolam rescue dose was 1.1 mg in the dexmedetomidine group, and 2.8 mg in the placebo group. The difference in means in dose of rescue midazolam was -1.8 mg (95% CI: -2.7 - -0.86) favouring dexmedetomidine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics of dexmedetomidine has been assessed following short term IV administration in healthy volunteers and long term infusion in ICU population.</p><p><u>Distribution</u></p><p>Dexmedetomidine exhibits a two-compartment disposition model. In healthy volunteers it exhibits a rapid distribution phase with a central estimate of the distribution half-life (t1/2&alpha;) of about 6 minutes. The mean estimate of the terminal elimination half-life (t<sub>1/2</sub>) is approximately</p><p>1.9 to 2.5 h (min 1.35, max 3.68 h) and the mean estimate of the steady-state volume of distribution (Vss) is approximately 1.16 to 2.16 l/kg (90 to 151 litres). Plasma clearance (Cl) has a mean estimated value of 0.46 to 0.73 l/h/kg (35.7 to 51.1 l/h). The mean body weight associated with these Vss and Cl estimates was 69 kg. Plasma pharmacokinetics of dexmedetomidine is similar in the ICU population following infusion &gt;24 h. The estimated pharmacokinetic parameters are: t1/2 approximately 1.5 hours, Vss approximately 93 litres and Cl approximately 43 l/h. The pharmacokinetics of dexmedetomidine is linear in the dosing range from 0.2 to 1.4 &mu;g/kg/h and it does not accumulate in treatments lasting up to 14 days. Dexmedetomidine is 94% bound to plasma proteins. Plasma protein binding is constant over&nbsp;the concentration range of 0.85 to 85 ng/ml. Dexmedetomidine binds to both human serum albumin and Alpha-1-acid glycoprotein with serum albumin as the major binding protein of dexmedetomidine in plasma.</p><p>&nbsp;</p><p><strong><u>Biotransformation and Elimination</u></strong></p><p>Dexmedetomidine is eliminated by extensive metabolism in the liver. There are three types of initial metabolic reactions; direct N-glucuronidation, direct N-methylation and cytochrome P450 catalysed oxidation. The most abundant circulating dexmedetomidine metabolites are two isomeric N-glucuronides. Metabolite H-1, N-methyl 3-hydroxymethyl dexmedetomidine O-glucuronide, is also a major circulating product of dexmedetomidine biotransformation. Cytochrome P-450 catalyses the formation of two minor circulating metabolites, 3- hydroxymethyl dexmedetomidine produced by hydroxylation at the 3-methyl group of dexmedetomidine and H-3 produced by oxidation in the imidazole ring. Available data suggest that the formation of the oxidised metabolites is mediated by several CYP forms (CYP2A6, CYP1A2, CYP2E1, CYP2D6 and CYP2C19). These metabolites have negligible pharmacological activity.</p><p>Following IV administration of radiolabeled dexmedetomidine an average 95% of radioactivity was recovered in the urine and 4% in the faeces after nine days. The major urinary metabolites are the two isomeric N-glucuronides, which together accounted for approximately 34% of the dose and N-methyl 3-hydroxymethyl dexmedetomidine O-glucuronide that accounted for 14.51% of the dose. The minor metabolites dexmedetomidine carboxylic acid, 3-hydroxymethyl dexmedetomidine and its O-glucuronide individually comprised 1.11 to 7.66% of the dose. Less than 1% of unchanged parent drug was recovered in the urine. Approximately 28% of the urinary metabolites are unidentified minor metabolites.</p><p>&nbsp;</p><p><strong><u>Special Populations</u></strong></p><p>No major pharmacokinetic differences have been observed based on gender or age. Dexmedetomidine plasma protein binding is decreased in subjects with hepatic impairment compared with healthy subjects. The mean percentage of unbound dexmedetomidine in plasma ranged from 8.5% in healthy subjects to 17.9% in subjects with severe hepatic impairment. Subjects with varying degrees of hepatic impairment (Child-Pugh Class A, B, or C) had decreased hepatic clearance of dexmedetomidine and prolonged plasma elimination t<sub>1/2</sub>. The mean plasma clearance values of unbound dexmedetomidine for subjects with mild, moderate, and severe hepatic impairment were 59%, 51% and 32% of those observed in the normal healthy subjects, respectively. The mean t<sub>1/2</sub> for the subjects with mild, moderate or severe hepatic impairment was prolonged to 3.9, 5.4, and 7.4 hours, respectively. Although dexmedetomidine is administered to effect, it may be necessary to consider initial/maintenance dose reduction in patients with hepatic impairment depending on the degree of impairment and the response.</p><p>&nbsp;</p><p>The pharmacokinetics of dexmedetomidine in subjects with severe renal impairment (creatinine clearance &lt;30 ml/min) is not altered relative to healthy subjects.</p><p>Data in new-born infants (28 - 44 weeks gestation) to children 17 years of age are limited. Dexmedetomidine half life in children (1 months to 17 years) appears similar to that seen in adults, but in new-born infants (under 1 month) it appears higher. In the age groups 1 months to 6 years, body weight-adjusted plasma clearance appeared higher but decreased in older children. Body weight-adjusted plasma clearance in new-born infants (under 1 month) appeared lower (0.9 l/h/kg) than in the older groups due to immaturity. The available data is summarised in the following table;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4" style="vertical-align:top"><p>Mean (95% CI)</p></td></tr><tr><td style="vertical-align:top"><p>Age</p></td><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>Cl (l/h/kg)</p></td><td style="vertical-align:top"><p>t<sub>1/2</sub> (h)</p></td></tr><tr><td style="vertical-align:top"><p>Under 1 month</p></td><td style="vertical-align:top"><p>28</p></td><td style="vertical-align:top"><p>0.93</p><p>(0.76, 1.14)</p></td><td style="vertical-align:top"><p>4.47</p><p>(3.81, 5.25)</p></td></tr><tr><td style="vertical-align:top"><p>1 to &lt; 6 months</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>1.21</p><p>(0.99, 1.48)</p></td><td style="vertical-align:top"><p>2.05</p><p>(1.59, 2.65)</p></td></tr><tr><td style="vertical-align:top"><p>6 to &lt; 12 months</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>1.11</p><p>(0.94, 1.31)</p></td><td style="vertical-align:top"><p>2.01</p><p>(1.81, 2.22)</p></td></tr><tr><td style="vertical-align:top"><p>12 to &lt; 24 months</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>1.06</p><p>(0.87, 1.29)</p></td><td style="vertical-align:top"><p>1.97</p><p>(1.62, 2.39)</p></td></tr><tr><td style="vertical-align:top"><p>2 to &lt; 6 years</p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>1.11</p><p>(1.00, 1.23)</p></td><td style="vertical-align:top"><p>1.75</p><p>(1.57, 1.96)</p></td></tr><tr><td style="vertical-align:top"><p>6 to &lt; 17 years</p></td><td style="vertical-align:top"><p>28</p></td><td style="vertical-align:top"><p>0.80</p><p>(0.69, 0.92)</p></td><td style="vertical-align:top"><p>2.03</p><p>(1.78, 2.31)</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, single and repeated dose toxicity and genotoxicity.</p><p>In the reproductive toxicity studies, dexmedetomidine had no effect on male or female fertility in the rat, and no teratogenic effects were observed in the rat or rabbit. In the rabbit study intravenous administration of the maximum dose, 96 &mu;g/kg/day, produced exposures that aresimilar to those observed clinically. In the rat, subcutaneous administration at the maximum dose, 200 &mu;g/kg/day, caused an increase in embryofetal death and reduced the fetal body weight. These effects were associated with clear maternal toxicity. Reduced fetal body weight was noted also in the rat fertility study at dose 18 &mu;g/kg/day and was accompanied with delayed ossification at dose 54 &mu;g/kg/day. The observed exposure levels in the rat are below the clinical exposure range.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium Chloride</p><p>Water for Injection</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p><p>Compatibility studies have shown potential for adsorption of dexmedetomidine to some types of natural rubber. Although dexmedetomidine is dosed to effect, it is advisable to use components with synthetic or coated natural rubber gaskets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
After dilution
Chemical and physical in-use stability has been demonstrated for 24 hours at 30°C and 2- 8°C(except 20% mannitol).
From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to the use are the responsibility of the user and would not normally be longer than 24 hours at 2° to 8°C, unless dilution has taken place in controlled and validated aseptic conditions.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below the 30&deg;C.</p><p>For storage conditions after dilution of the medicinal product, refer section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The product is packed as 200 mcg in 2 mL USP Type I flint clear glass tubular vial, stoppered with 13 mm ready to sterilize Teflon coated rubber stopper sealed with 13 mm aluminium flip- off seal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Preparation of Solution</u></strong></p><p>Strict aseptic technique must always be maintained during handling of Dexmedetomidine Hydrochloride Injection.</p><p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</p><p>&nbsp;</p><p><strong>Dexmedetomidine Hydrochloride Injection, 200 mcg/2 mL (100 mcg/mL) </strong>Dexmedetomidine Hydrochloride Injection must be diluted with 0.9% sodium chloride injection to achieve required concentration (4 mcg/mL) prior to administration. Preparation of solutions is the same, whether for the loading dose or maintenance infusion.</p><p>To prepare the infusion, withdraw 2 mL of Dexmedetomidine Hydrochloride Injection, and add to 48 mL of 0.9% sodium chloride injection to a total of 50 mL. Shake gently to mix well.</p><p>&nbsp;</p><p><strong>Dexmedetomidine Hydrochloride Injection in 0.9% Sodium Chloride Injection, 80 mcg/20 mL (4 mcg/mL), 200 mcg/50 mL (4 mcg/mL) and 400 mcg/100 mL (4 mcg/mL) </strong>Dexmedetomidine Hydrochloride Injection in 0.9% Sodium Chloride Injection is supplied in glass containers containing a premixed, ready to use dexmedetomidine hydrochloride solution in 0.9% sodium chloride in water. No further dilution of these preparations are necessary.</p><p>Administration with Other Fluids</p><p>Dexmedetomidine Hydrochloride infusion should not be co-administered through the same intravenous catheter with blood or plasma because physical compatibility has not been established.</p><p>Dexmedetomidine Hydrochloride Injection has been shown to be incompatible when administered with the following drugs: amphotericin B, diazepam.</p><p>Dexmedetomidine Hydrochloride Injection has been shown to be compatible when administered with the following intravenous fluids:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.9% sodium chloride in water</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5% dextrose in water</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 20% mannitol</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lactated Ringer&#39;s solution</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 100 mg/mL magnesium sulfate solution</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.3% potassium chloride solution</p><p>&nbsp;</p><p>Compatibility with Natural Rubber</p><p>Compatibility studies have demonstrated the potential for absorption of Dexmedetomidine Hydrochloride Injection to some types of natural rubber. Although Dexmedetomidine Hydrochloride Injection is dosed to effect, it is advisable to use administration components made with synthetic or coated natural rubber gaskets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Boston Oncology Arabia Sudair Industrial City, Sudair, Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                02/2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>